Introduction
Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib, an oral targeted anticancer medicine that inhibits fibroblast growth factor receptors 1, 2 and 3 (FGFR1, FGFR2 and FGFR3).
Pemigatinib is used in specific cancer treatment settings where molecular testing identifies relevant genetic abnormalities. Its clinical role is based on the involvement of abnormal FGFR signaling in the growth and survival of certain cancer cells.
Unlike medicines that act broadly against rapidly dividing cells, pemigatinib targets selected proteins involved in cancer-related signaling pathways. This makes it an example of precision oncology, in which treatment selection depends partly on the molecular characteristics of a patient’s disease.
The clinical information on this page explains pemigatinib’s pharmacological activity, recognized treatment indications, molecular testing requirements, treatment schedules and important monitoring considerations.
Pharmacological Classification
Pemigatinib is classified as a small-molecule kinase inhibitor. More specifically, it is a selective inhibitor of FGFR1, FGFR2 and FGFR3.
FGFR proteins belong to the receptor tyrosine kinase family. They are involved in cellular communication and regulate biological processes such as:
- Cell growth and proliferation.
- Cell differentiation.
- Cell survival.
- Tissue development.
- Blood-vessel formation.
- Cellular response to growth factors.
Normal FGFR activity is important for healthy tissue function. However, certain genetic alterations can cause abnormal receptor signaling and contribute to cancer development.
Mechanism of Action
Pemigatinib inhibits the kinase activity of FGFR1, FGFR2 and FGFR3.
In certain tumors, genetic alterations such as FGFR2 fusions or rearrangements can cause abnormal activation of signaling pathways. These pathways may provide cancer cells with signals that support growth and survival.
By inhibiting the relevant FGFR proteins, pemigatinib interferes with these signaling processes.
The clinical relevance of this mechanism depends on the presence of the appropriate molecular abnormality. A tumor that does not contain a qualifying FGFR alteration should not automatically be considered suitable for pemigatinib treatment.
Clinical Use in FGFR2-Altered Cholangiocarcinoma
Cholangiocarcinoma is a malignant disease that develops in the bile ducts. It may occur within the liver or in the bile ducts outside the liver.
Some cholangiocarcinomas contain FGFR2 gene fusions or other qualifying rearrangements. These alterations can lead to abnormal FGFR signaling and contribute to tumor development.
Under U.S. prescribing information for the reference product, pemigatinib is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma containing an FGFR2 fusion or another qualifying rearrangement, as detected by an FDA-approved test.
The European indication is for adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that has progressed after at least one previous systemic therapy.
The exact approved indication depends on the country and applicable regulatory labeling.
Pemigatinib is not intended for all patients with bile duct cancer. Molecular confirmation and assessment of previous treatment are important parts of eligibility evaluation.
Clinical Use in FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
The U.S. prescribing information for pemigatinib also includes an indication for adults with relapsed or refractory myeloid/lymphoid neoplasms containing an FGFR1 rearrangement.
These are uncommon blood-related cancers involving abnormal growth and development of blood-forming cells.
An FGFR1 rearrangement can result in abnormal signaling that contributes to disease progression. Pemigatinib targets this abnormality by inhibiting FGFR activity.
The clinical management of these conditions differs from the management of cholangiocarcinoma. The treatment schedule, monitoring plan and clinical assessment must be based on the specific diagnosis and applicable prescribing information.
Importance of Molecular Testing
Molecular testing is essential when determining whether pemigatinib may be appropriate.
For the cholangiocarcinoma indication, testing must identify an eligible FGFR2 fusion or rearrangement.
For the U.S. FGFR1-rearranged myeloid/lymphoid neoplasm indication, testing must establish the relevant FGFR1 rearrangement.
Testing may involve validated molecular diagnostic methods selected by the treating team.
A pathology report or general cancer diagnosis alone may not provide enough information to establish eligibility. The healthcare professional must review the exact molecular result and determine whether it meets the applicable treatment requirements.
Treatment Schedule and Clinical Monitoring
For qualifying cholangiocarcinoma, the U.S. reference-product regimen is 13.5 mg once daily for 14 consecutive days, followed by seven days without treatment. This forms a 21-day treatment cycle.
For qualifying FGFR1-rearranged myeloid/lymphoid neoplasms, the U.S. labeled regimen is 13.5 mg once daily continuously.
These are different treatment schedules. Patients must follow the regimen prescribed for their specific indication and must not transfer one schedule to another.
Monitoring is necessary throughout treatment. It may include:
- Blood phosphate measurements.
- Kidney and liver function assessments.
- Eye examinations.
- Evaluation of skin and nail changes.
- Review of gastrointestinal symptoms.
- Assessment of treatment tolerance.
- Review of other medicines and possible interactions.
Hyperphosphatemia
Hyperphosphatemia, or an elevated phosphate level in the blood, is an important adverse reaction associated with pemigatinib.
FGFR inhibition can affect phosphate regulation. Elevated phosphate levels may require dietary management, phosphate-lowering treatment or adjustment of the pemigatinib dose.
If phosphate levels become significantly elevated, healthcare professionals may temporarily interrupt treatment or modify the dose according to the prescribing information.
Patients should attend scheduled blood tests and follow the medical team’s instructions about dietary measures and treatment.
Ocular Safety
Pemigatinib can cause ocular adverse reactions, including retinal pigment epithelial detachment (RPED).
Patients should receive an eye examination, including optical coherence tomography (OCT), before starting treatment. Under U.S. reference-product labeling, eye examinations are recommended every two months during the first six months and every three months afterward while receiving treatment, with additional examinations when clinically indicated.
Symptoms that require prompt medical attention include:
- Blurred vision.
- New visual floaters.
- Flashes of light.
- Changes in color perception.
- Other new or worsening visual disturbances.
Patients should not wait for their next scheduled examination if they experience new visual symptoms.
Other Clinical Safety Considerations
Pemigatinib may also cause nail disorders, hair loss, diarrhea, fatigue, nausea, stomatitis, dry eyes, dry mouth and skin reactions.
Drug interactions are important because medicines that affect CYP3A enzymes may change pemigatinib exposure. Strong or moderate CYP3A inducers and inhibitors require particular attention under prescribing guidance.
Patients should tell their healthcare professionals about all prescription medicines, nonprescription products, vitamins and herbal preparations they use.
Clinical Information and Individual Treatment Decisions
Clinical information describes how a medicine has been studied and how it is used under defined treatment conditions. It does not determine whether a particular patient should receive treatment.
A qualified specialist must consider the cancer diagnosis, molecular test results, previous therapies, overall health, organ function and potential risks.
Pemitinib-specific manufacturing and regulatory details must also be verified independently from the established reference-product information.
Conclusion
Pemigatinib is a targeted FGFR inhibitor with recognized clinical applications in selected patients with FGFR2-altered cholangiocarcinoma and, under U.S. labeling, FGFR1-rearranged myeloid/lymphoid neoplasms.
Its use depends on molecular testing, appropriate prescribing and ongoing monitoring. Understanding its clinical profile can help patients and caregivers have more informed discussions with their healthcare professionals.